APA (7th ed.) Citation

X, W., L, M., WB, L., YM, K., XM, Q., JF, W., & Y, K. (2026). Recombinant human thrombopoietin for chronic liver disease-associated thrombocytopenia with or without concomitant infections: A real-world retrospective study. Frontiers in pharmacology, 17, 1732969. https://doi.org/10.3389/fphar.2026.1732969

Chicago Style (17th ed.) Citation

X, Wei, Ma L, Liu WB, Kuang YM, Qin XM, Wei JF, and Kang Y. "Recombinant Human Thrombopoietin for Chronic Liver Disease-associated Thrombocytopenia with or Without Concomitant Infections: A Real-world Retrospective Study." Frontiers in Pharmacology 17 (2026): 1732969. https://doi.org/10.3389/fphar.2026.1732969.

MLA (9th ed.) Citation

X, Wei, et al. "Recombinant Human Thrombopoietin for Chronic Liver Disease-associated Thrombocytopenia with or Without Concomitant Infections: A Real-world Retrospective Study." Frontiers in Pharmacology, vol. 17, 2026, p. 1732969, https://doi.org/10.3389/fphar.2026.1732969.